Zymeworks ZYME Development support payments — Research and development collaborations
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zymeworks's development support payments — research and development collaborations.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zymeworks's development support payments — research and development collaborations?
- Zymeworks (ZYME) reported development support payments — research and development collaborations of $392K in Q1 2026.
- How has Zymeworks's development support payments — research and development collaborations changed year-over-year?
- Zymeworks's development support payments — research and development collaborations decreased by 91.3% year-over-year, from $4.49M to $392K.
- What is the long-term trend for Zymeworks's development support payments — research and development collaborations?
- Over 3 years (2021 to 2025), Zymeworks's development support payments — research and development collaborations has grown at a -0.4% compound annual growth rate (CAGR), from $5.68M to $5.62M.
- What does development support payments — research and development collaborations mean?
- This metric represents revenue recognized from research and development collaboration agreements, specifically covering payments for development support and related services provided to partners. It reflects the company's ability to monetize its proprietary technology platforms and drug development expertise through strategic alliances. These payments serve as a key indicator of the company's success in leveraging its R&D engine to generate non-dilutive capital while advancing its clinical pipeline.